Cara | $8,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Waiv, formerly Owkin Dx
France
- Paris
- 13/03/2026
- Unknown
- $33,000,000
Waiv has evolved to meet this moment:
Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics.
Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind.
Waiv, a spin-out of Owkin (https://www.owkin.com/), capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC (https://www.owkin.com/diagnostics/rlapsrisk-bc), to unlock morphological insights and future-proof the clinical diagnostic workflow.
- Industry Biotechnology Research
- Website https://wearewaiv.com/
- LinkedIn https://www.linkedin.com/company/we-are-waiv/
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Variance | $21,500,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
TippingPoint Biosciences | $4,500,000 | (Apr 2, 2026)
Quantcore | $3,318,962 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)
Semarion | $3,800,000 | (Apr 2, 2026)
Via Separations | $36,000,000 | (Apr 2, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)